USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
DEKK-TEC, INC.
Address:
725 TOPAZ STREET
NEW ORLEANS, LA 70124-
Phone:
N/A
URL:
N/A
EIN:
172097699
DUNS:
139242184
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,108,638.00 9
SBIR Phase II $5,405,723.00 6
STTR Phase I $100,000.00 1

Award List:

PHENYLHYDRAZONES WITH ANTIESTROGEN ACTIVITIES

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,930.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

PHENYLHYDRAZONES WITH ANTIESTROGEN ACTIVITIES

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$440,486.00
Agency:
HHS
Principal Investigator:
Abstract:
Substituted benzophenone phenylhydrazones have been synthesized and have demonstrated good antiestrogen activities with low to absent intrinsic estrogenicity (in animmature rat uteri assay). 4,4(,)-dihydroxybenzophenone-2, 4-dinitrophenylhydrazone (a-007) has demonstrated a 38-percent cr with an… More

ARYL HYDRAZONES WITH ANTICANCER ACTIVITIES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,998.00
Agency:
HHS
Principal Investigator:
Lee R Morgan
Abstract:
Substituted benzophenone phenylhydrazones have been identified that possess antiestrogen activities with absent estrogenicity. 4, 4'-dihydroxybenzophenone-2, 4-dinitrophenylhdrazone (a-007) has demonstrated antiestrogenic activities at low concentrations and cytotoxic activities at higher… More

Pyrromethene Boron Difluorides in PDT

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Lee Roy Morgan
Abstract:
The overall objective is to develop new anticancer agents which are cytotoxic in photodynamic therapy (PDT). It has been shown by Morgan and Boyer that pyrromethene boron difluoride (P-BF2) complexes can offer this property. In Phase I, substituted (P-BF2) complexes will be prepared, characterized… More

ISOPHOSPHORAMIDE MUSTARD ANALOGS FOR CANCER THERAPY

Award Year / Program / Phase:
1998 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Morgan
Research Institution:
Southern Research Institute
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Lee R. Morgan
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$126,956.00
Agency:
HHS
Principal Investigator:
Lee R. Morgan
Abstract:
N/a

A-007: IMMUNE MODULATION OF HPV - CERVICAL CANCER

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$191,517.00
Agency:
HHS
Principal Investigator:
Lee R. Morgan
Abstract:
DESCRIPTION: (Applicant's Description) 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has recently completed a Phase I clinical trial in advanced cancer with minimal toxicity and objective responses noted. Preliminary… More

CLINICAL DEVELOPMENT OF 4-HYDROPEROXYIFOSFAMIDE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$185,641.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of the proposed research is to synthesize 4-hydroperoxyifosfamide (HOO-IFOS) in sufficient quantity for evaluation in vivo against a human osteosarcoma xenograft and additional tumor xenografts of breast, lung (small cell and non-small cell) and… More

A-007: Immune Modulation of HPV - Associated Neoplasia

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$2,300,487.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In a recent study, A-007 was administered as a topical gel to treat anogenital cancers associated with… More

Clinical Development of 4-Hydroperoxyifosfamide

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$539,124.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): 4-Hydroperoxyifosfamide (HOO-IFOS) is a stable, pre-activated form (peroxide) of 4-HO-IFOS, the initial metabolite of Ifosfamide (IFOS). Under physiological conditions HOO-IFOS under goes spontaneously ring opening and conversion to isophosphoramide mustard… More

Camptothecin Analogs for Cancer Therapy

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$158,895.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, are novel camptothecins that were designed to be used in the treatment of childhood neuroblastoma. These CPT analogs are lactones that have increased activity in acidic hypoxia… More

SBIR TOPIC 232 MANUFACTURE OF 4-DEMETHYL 4-CHOLESTEROLYL-PENCLOMEDINE

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
HHS
Principal Investigator:
Roy Lee
Abstract:
N/a

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$272,657.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative of 4-demethyl-penclomedine (DM-PEN) in patients with ad vanced cancer. The latter is the antitumor… More

Camptothecin Analogs for Cancer Therapy

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$837,217.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic tumor tissues, characteristic of fast growing cancers t hat characteristically have deficient… More

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,161,453.00
Agency:
HHS
Principal Investigator:
Lee R. Morgan – 504-583-6135
Abstract:
DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbonate as anticancer therapy for patients with advanced cancer in a Phase II clinical trial. During… More